Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB)

被引：15
|
作者：
Hottinger, Andreas Felix
Sanson, Marc
Moyal, Elizabeth
Delord, Jean-Pierre
De Micheli, Rita
Rezai, Keyvan
Leung, Abraham C. F.
Perez, Susan
Bekradda, Mohamed
Lachaux, Nicolas
Lokiec, Francois Marc
Chinot, Olivier L.
机构：
[1] CHUV Univ Hosp, Lausanne, Switzerland
[2] Grp Hosp Univ Salpetriere, Paris, France
[3] IUCT O, Inst Claudius Regaud, Toulouse, France
[4] Inst Claudius Regaud, Toulouse, France
[5] CHU Vaudois, Lausanne, Switzerland
[6] Univ Lausanne Hosp, Lausanne, Switzerland
[7] Inst Curie Hop Rene Huguenin, St Cloud, France
[8] Genentech BioOnc, San Francisco, CA USA
[9] Merck Res Labs, Rahway, NJ USA
[10] Oncol Therapeut Dev, Clichy, France
[11] Aix Marseille Univ, Serv Neuro Oncol, AP HM, CHU Timone, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14123
引用
收藏
页数：2
相关论文
共 23 条
  • [1] DOSE OPTIMIZATION OF MK-8628 (OTX015), A SMALL MOLECULE INHIBITOR OF BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Hottinger, A. F.
    Sanson, M.
    Moyal, E.
    Delord, J.
    Rezai, K.
    Leung, A.
    Perez, S.
    Bekradda, M.
    Lachaux, N.
    Chinot, O.
    [J]. NEURO-ONCOLOGY, 2016, 18 : 56 - 56
  • [2] A phase lb trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors
    Massard, C.
    Soria, J. C.
    Stathis, A.
    Delord, J. P.
    Awada, A.
    Peters, S.
    Lewin, J.
    Bekradda, M.
    Rezai, K.
    Zeng, Z.
    Azher, H.
    Perez, S.
    Siu, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S2 - S3
  • [3] Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
    Vazquez, Ramiro
    Licandro, Simonetta Andrea
    Astorgues-Xerri, Lucile
    Lettera, Emanuele
    Panini, Nicolo
    Romano, Michela
    Erba, Eugenio
    Ubezio, Paolo
    Bello, Ezia
    Libener, Roberta
    Orecchia, Sara
    Grosso, Federica
    Riveiro, Maria Eugenia
    Cvitkovic, Esteban
    Bekradda, Mohamed
    D'Incalci, Maurizio
    Frapolli, Roberta
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 197 - 207
  • [4] Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells
    Roulin, Louise
    Ali, Ashfaq
    Masse, Aline
    Coude, Marie-Magdelaine
    Bluteau, Dominique
    Braun, Thorsten
    Berrou, Jeanning
    Bluteau, Olivier
    Delord, Marc
    Riveiro, Maria Eugenia
    Herait, Patrice Edouard
    Soulier, Jean
    Baruchel, Andre
    Gardin, Claude
    Dombret, Herve
    Itzykson, Raphael
    [J]. BLOOD, 2015, 126 (23)
  • [5] Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
    Gaudio, Eugenio
    Tarantelli, Chiara
    Ponzoni, Maurilio
    Odore, Elodie
    Rezai, Keyvan
    Bernasconi, Elena
    Cascione, Luciano
    Rinaldi, Andrea
    Stathis, Anastasios
    Riveiro, Eugenia
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. ONCOTARGET, 2016, 7 (36) : 58142 - 58147
  • [6] Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
    Stathis, Anastasios
    Zucca, Emanuele
    Bekradda, Mohamed
    Gomez-Roca, Carlos
    Delord, Jean-Pierre
    Rouge, Thibault de La Motte
    Uro-Coste, Emmanuelle
    de Braud, Filippo
    Pelosi, Giuseppe
    French, Christopher A.
    [J]. CANCER DISCOVERY, 2016, 6 (05) : 492 - 500
  • [7] OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models
    Berenguer-Daize, Caroline
    Astorgues-Xerri, Lucile
    Odore, Elodie
    Cayol, Mylene
    Cvitkovic, Esteban
    Noel, Kay
    Bekradda, Mohamed
    MacKenzie, Sarah
    Rezai, Keyvan
    Lokiec, Francois
    Riveiro, Maria E.
    Ouafik, L'Houcine
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (09) : 2047 - 2055
  • [8] Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models
    Astorgues-Xerri, Lucile
    Vazquez, Ramiro
    Odore, Elodie
    Rezai, Keyvan
    Kahatt, Carmen
    Mackenzie, Sarah
    Bekradda, Mohamed
    Coude, Marie-Magdelaine
    Dombret, Herve
    Gardin, Claude
    Lokiec, Francois
    Raymond, Eric
    Noel, Kay
    Cvitkovic, Esteban
    Herait, Patrice
    Bertoni, Francesco
    Riveiro, Maria E.
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 3067 - 3070
  • [9] The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation
    Hu, Xiao
    Schewitz-Bowers, Lauren P.
    Lait, Philippa J. P.
    Copland, David A.
    Stimpson, Madeleine L.
    Li, Jing Jing
    Liu, Yizhi
    Dick, Andrew D.
    Lee, Richard W. J.
    Wei, Lai
    [J]. CURRENT MOLECULAR MEDICINE, 2018, 18 (09) : 594 - 601
  • [10] Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
    Boi, Michela
    Todaro, Maria
    Vurchio, Valentina
    Yang, Shao Ning
    Moon, John
    Kwee, Ivo
    Rinaldi, Andrea
    Pan, Heng
    Crescenzo, Ramona
    Cheng, Mangeng
    Cerchietti, Leandro
    Elemento, Olivier
    Riveiro, Maria E.
    Cvitkovic, Esteban
    Bertoni, Francesco
    Inghirami, Giorgio
    [J]. ONCOTARGET, 2016, 7 (48) : 79623 - 79639
123